Literature DB >> 1721674

Genetic characterization of the O4 polysaccharide gene cluster from Escherichia coli.

G E Haraguchi1, U Zähringer, B Jann, K Jann, R A Hull, S I Hull.   

Abstract

The Escherichia coli O4 serotype is among those commonly isolated from urinary tract infections. In order to study the genetics of the O-antigen, the O4 biosynthesis genes from a uropathogenic E. coli have previously been cloned into E. coli K-12. A subclone, GH58, has been identified which reacts with antisera against the O4 serotype. In contrast to the wild-type parental strain, lipopolysaccharide (LPS) from this clone is devoid of rhamnose and does not cross-react with O18 antisera. The recombinant plasmid from GH58, pGH58, was used to transform the rfb deletion strain HU1190. The resultant strain agglutinates in O4 antisera, but produces unpolymerized LPS. Escherichia coli K-12 strains HB101 and RC712 containing pGH58 produce polymerized LPS, indicating that the genetic background of the host can influence the LPS encoded by recombinant molecules. A cosmid, pGH84, has been identified which encompasses the entire pGH58 gene sequences and includes an additional 34 kilobases of DNA. HU1190 containing this cosmid agglutinates in O4 antisera and produces a polymerized LPS. By constructing several deletion subclones of pGH84, we have localized the genes necessary for polymerized LPS to a 5.5 kb ClaI-BamHI fragment. P1 transductants that make polymerized and unpolymerized O4 LPS have also been identified.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1721674     DOI: 10.1016/0882-4010(91)90080-t

Source DB:  PubMed          Journal:  Microb Pathog        ISSN: 0882-4010            Impact factor:   3.738


  9 in total

Review 1.  Genetics of lipopolysaccharide biosynthesis in enteric bacteria.

Authors:  C A Schnaitman; J D Klena
Journal:  Microbiol Rev       Date:  1993-09

2.  Lipopolysaccharide smooth-rough phase variation in bacteria of the genus Chlamydia.

Authors:  M Lukácová; M Baumann; L Brade; U Mamat; H Brade
Journal:  Infect Immun       Date:  1994-06       Impact factor: 3.441

3.  Identification of the O antigen polymerase (rfc) gene in Escherichia coli O4 by insertional mutagenesis using a nonpolar chloramphenicol resistance cassette.

Authors:  S Lukomski; R A Hull; S I Hull
Journal:  J Bacteriol       Date:  1996-01       Impact factor: 3.490

4.  Comparison of loss of serum resistance by defined lipopolysaccharide mutants and an acapsular mutant of uropathogenic Escherichia coli O75:K5.

Authors:  S M Burns; S I Hull
Journal:  Infect Immun       Date:  1998-09       Impact factor: 3.441

5.  Molecular cloning of the rfb region of Klebsiella pneumoniae serotype O1:K20: the rfb gene cluster is responsible for synthesis of the D-galactan I O polysaccharide.

Authors:  B R Clarke; C Whitfield
Journal:  J Bacteriol       Date:  1992-07       Impact factor: 3.490

6.  Cloning and analysis of duplicated rfbM and rfbK genes involved in the formation of GDP-mannose in Escherichia coli O9:K30 and participation of rfb genes in the synthesis of the group I K30 capsular polysaccharide.

Authors:  P Jayaratne; D Bronner; P R MacLachlan; C Dodgson; N Kido; C Whitfield
Journal:  J Bacteriol       Date:  1994-06       Impact factor: 3.490

7.  Structure of the O antigen of Escherichia coli K-12 and the sequence of its rfb gene cluster.

Authors:  G Stevenson; B Neal; D Liu; M Hobbs; N H Packer; M Batley; J W Redmond; L Lindquist; P Reeves
Journal:  J Bacteriol       Date:  1994-07       Impact factor: 3.490

8.  Identification of rfbA, involved in B-band lipopolysaccharide biosynthesis in Pseudomonas aeruginosa serotype O5.

Authors:  T Dasgupta; J S Lam
Journal:  Infect Immun       Date:  1995-05       Impact factor: 3.441

9.  Cytokine profiles of umbilical cord blood mononuclear cells upon in vitro stimulation with lipopolysaccharides of different vaginal gram-negative bacteria.

Authors:  Edith Reuschel; Martina Toelge; Kathrin Entleutner; Ludwig Deml; Birgit Seelbach-Goebel
Journal:  PLoS One       Date:  2019-09-19       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.